This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Advancing iOWH032: Novel Antisecretory Drug for the Treatment of Cholera

PATH and partners are developing iOWH032 as a complement to oral rehydration solution for diarrheal disease treatment. Acting via inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel, iOWH032 is a novel, low-molecular-weight compound intended to reduce fluid and electrolyte loss in cases of cholera toxin-induced secretory diarrhea.

Publication date: August 2017

Advancing iOWH032: Novel Antisecretory Drug for the Treatment of Cholera

628.1 KB PDF

Hard copies are not available.

View Resource